IMMUCELL CORP /DE/ Cash Flow Statement
ICCC|10 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$357,903
FY2025
Free Cash Flow
-$107,822
FY2025
Capital Expenditures
$465,725
Cash used for long-term assets
Dividends Paid
N/A
FY2025
IMMUCELL CORP /DE/ generated $357,903 in operating cash flow and negative free cash flow of $107,822 in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Conservative debt: Debt-to-equity ratio of 0.27
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.2M | -$5.8M | -$2.5M | $508.4K | $1.2M | $117.4K | $89.5K | -$409.5K | -$384.7K | -$216.5K |
| Depreciation & Amortization | $2.7M | $2.7M | $2.5M | $783.3K | $525.9K | $414.3K | $399.6K | $413.1K | $416.9K | $394.3K |
| Operating Cash Flow | $357.9K | -$4.7M | -$1.5M | -$222.3K | $2.9M | $1.1M | $344.4K | -$37.3K | -$808.6K | -$109.7K |
| Capital Expenditures | $465.7K | $1.9M | $4.0M | $3.6M | $2.7M | $597.7K | $275.4K | $243.7K | $116.5K | $459.5K |
| Free Cash Flow | -$107.8K | -$6.6M | -$5.5M | -$3.8M | $181.0K | $501.0K | $69.0K | -$281.1K | -$925.2K | -$569.2K |
| FCF Margin | -0.4% | -37.6% | -29.7% | -39.9% | 1.8% | 8.3% | 1.3% | -5.5% | -21.1% | -12.6% |